We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.84%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.05B
AUM Growth
+$146M
Cap. Flow
-$430M
Cap. Flow %
-8.52%
Top 10 Hldgs %
43.4%
Holding
134
New
26
Increased
24
Reduced
35
Closed
22

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$129M
2
MRK icon
Merck
MRK
+$76.6M
3
GH icon
Guardant Health
GH
+$43.7M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$31.5M
5
QURE icon
uniQure
QURE
+$28.3M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$87M
2
LLY icon
Eli Lilly
LLY
+$65.3M
3
APLS
Apellis Pharmaceuticals
APLS
+$61M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.8M
5
CI icon
Cigna
CI
+$56.4M

Sector Composition

Rank Sector Weight
1 Healthcare 90.42%
2 Miscellaneous 9.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
26
Mineralys Therapeutics
MLYS
$2.26B
$55.6M 1.1%
2,052,900
+1,072,500
+109% +$31.5M
PRAX icon
27
Praxis Precision Medicines
PRAX
$9.71B
$55.6M 1.1%
172,500
+78,000
+83% +$24.1M
PFE icon
28
Pfizer
PFE
$159B
$54.7M 1.08%
1,946,500
+293,600
+18% +$7.82M
DYN icon
29
Dyne Therapeutics
DYN
$4.66B
$52.9M 1.05%
2,917,884
+715,700
+32% +$12.3M
NTRA icon
30
Natera
NTRA
$47.2B
$52.4M 1.04%
262,000
-103,800
-28% -$22.3M
ABVX
31
Abivax
ABVX
$9.81B
$51.9M 1.03%
465,700
+97,800
+27% +$11.6M
UPB
32
Upstream Bio Inc
UPB
$368M
$51.2M 1.02%
5,693,589
– –
DHR icon
33
Danaher
DHR
$152B
$50.4M 1%
265,800
-34,000
-11% -$7.24M
CAI
34
Caris Life Sciences
CAI
$7.24B
$50.2M 0.99%
2,806,811
-309,200
-10% -$6.76M
RCEL icon
35
Avita Medical
RCEL
$320M
$42.5M 0.84%
+544,895
New +$2.29M
ASND icon
36
Ascendis Pharma A/S
ASND
$16.2B
$41.6M 0.83%
181,977
+10,000
+6% +$2.24M
STTK icon
37
Shattuck Labs
STTK
$719M
$40.5M 0.8%
6,306,127
– –
GH icon
38
Guardant Health
GH
$21.8B
$40.2M 0.8%
+435,200
New +$43.7M
ALNY icon
39
Alnylam Pharmaceuticals
ALNY
$31.5B
$39.4M 0.78%
119,000
-169,800
-59% -$57.8M
PRLD icon
40
Prelude Therapeutics
PRLD
$456M
$37.3M 0.74%
10,909,256
– –
CRNX icon
41
Crinetics Pharmaceuticals
CRNX
$9B
$36.3M 0.72%
999,000
– –
AXSM icon
42
Axsome Therapeutics
AXSM
$10.5B
$36.2M 0.72%
213,921
-39,200
-15% -$6.77M
QURE icon
43
uniQure
QURE
$3.39B
$34.9M 0.69%
2,136,149
+1,398,749
+190% +$28.3M
ORIC icon
44
Oric Pharmaceuticals
ORIC
$1.38B
$34.1M 0.68%
2,693,929
-947,827
-26% -$10.8M
ELV icon
45
Elevance Health
ELV
$86.3B
$33.6M 0.67%
114,700
+15,600
+16% +$5.13M
RLMD icon
46
Relmada Therapeutics
RLMD
$466M
$32.8M 0.65%
4,715,864
+2,105,264
+81% +$9.96M
FBRX icon
47
Forte Biosciences
FBRX
$31M 0.61%
1,196,955
– –
TRVI icon
48
Trevi Therapeutics
TRVI
$2.39B
$29.3M 0.58%
2,454,400
-736,300
-23% -$8.24M
ESPR
49
DELISTED
Esperion Therapeutics
ESPR
$29M 0.57%
10,570,300
+4,604,802
+77% +$14.6M
NPCE icon
50
Neuropace
NPCE
$495M
$27.6M 0.55%
2,096,527
-309,808
-13% -$4.65M
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2026 Portfolio in Review

As of Q1 2026, OrbiMed held 134 positions worth $5.05B, up 3% from $4.9B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

OrbiMed withdrew a net $430M in Q1 2026, closing 22 positions and reducing 35 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in AstraZeneca worth $132M.

  • OrbiMed's largest Q1 2026 buy was AstraZeneca: 670,200 shares worth $132M.
  • OrbiMed added most to Mineralys Therapeutics in Q1 2026, an estimated $31.5M increase.
  • OrbiMed's biggest Q1 2026 reduction was Eli Lilly, cutting an estimated $65.3M.
  • OrbiMed fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 43% of its $5.05B portfolio in Q1 2026.
  • OrbiMed opened 26 new positions and closed 22 in Q1 2026.
  • OrbiMed's portfolio value rose 3% quarter-over-quarter to $5.05B.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.